Condition
Acute Respiratory Distress Syndrome
Acute respiratory distress syndrome is a serious lung condition in which inflammation and fluid leaking into the tiny air sacs stop oxygen from reaching the blood. Among supplements, only vasoactive intestinal peptide, also called aviptadil, has been studied, and the evidence is rated strong, but trials gave mixed results: a smaller trial found better survival at 60 days, while a larger one found no difference. So whether it helps remains uncertain, and the findings mostly come from people critically ill with COVID-19.
Sources: PMID 41368449; PMID 36193478
- Updated
- How we grade
- 53 studies cited
- Supplements studied
- 0
- Medicines and peptides
- 1
- Graded outcomes
- 1
No supplement studies yetWe haven’t found supplement studies for Acute Respiratory Distress Syndrome. The medicines and peptides studied for it are listed below.
Prescription medicines and peptides studied, for context
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| ARDS/Respiratory Failure Mixed results: Small RCT (n=196) showed improved 60-day survival with IV aviptadil vs placebo. Larger TESICO trial (n=461) found no difference in primary endpoint (alive and free from respiratory failure at day 60). Clinical benefit uncertain. | NoneNo effect | 8 studies | ||||
Studies that measured ards/respiratory failure
| ||||||
Key findings
- ARDS/Respiratory Failure
Studies cited
53 studies from PubMed
- Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.
- Aviptadil as a Promising Intervention: A Case Study for Transfusion-Related Acute Lung Injury Treatment in a Cardiac Patient.
- Vasoactive Intestinal Polypeptide for Patients Hospitalized With COVID-19 and Hypoxemic Respiratory Failure: Effect on Mortality-The TESICO Trial
- Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice.
- Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
- The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
- Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.
- The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
- Editorial: GPCR in Inflammatory and Cancer Diseases.
- Vasoactive Intestinal Peptide Changes the Frequency and Force of Myocardial Contraction in Rats.
- A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases
- Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway.
- Erectile dysfunction: a global review of intracavernosal injectables.
- Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future.
- Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery.
- The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.
- Vasoactive intestinal peptide in pulmonary arterial hypertension.
- Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease
- Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells
- Inhalation of vasoactive intestinal peptide in pulmonary hypertension
- Pulmonary arterial hypertension: on the way to a manageable disease.
- Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD.
- [Vasoactive intestinal peptide-producing tumor (ViPoma)].
- Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis
- Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells
- The significance of vasoactive intestinal peptide in immunomodulation.
- Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
- Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.
- Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases.
- Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide.
- Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease
- Immunobiology of vasoactive intestinal peptide (VIP).
- Vasoactive intestinal peptide mediation of development and functions of T lymphocytes.
- Vasoactive intestinal peptide neurons as synaptic targets for vasopressin neurons in the suprachiasmatic nucleus. Double-label immunocytochemical demonstration in the rat.
- Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses.
- Expression of mRNA for vasoactive intestinal peptide in normal human colon and during inflammation.
- Oral sodium regulates extrahepatic metabolism of vasoactive intestinal peptide.
- Molecular characteristics of the cellular receptor for vasoactive intestinal peptide.
- Vasoactive intestinal peptide. Messenger in a neuroimmune axis.
- Vasoactive intestinal peptide (VIP): an amnestic neuropeptide.
- Vasoactive intestinal peptide (VIP), a putative neurotransmitter of nonadrenergic, noncholinergic (NANC) inhibitory innervation and its relevance to therapy.
- Vasoactive intestinal polypeptide and asthma.
- Vasoactive intestinal peptide and asthma.
- [Vasoactive intestinal peptide and substance P in the regulation of reproductive functions].
- Vasoactive intestinal peptide as a mediator of intercellular communication in the cerebral cortex. Release, receptors, actions, and interactions with norepinephrine.
- Vasoactive intestinal peptide as a modulator of lymphocyte and immune function.
- The role of vasoactive intestinal peptide and other neuropeptides in the regulation of the immune response in vitro and in vivo.
- Vasoactive intestinal peptide secreting tumors. Pathophysiological and clinical correlations.
- Vasoactive intestinal peptide in the lung.
- Vasoactive intestinal peptide as a coronary vasodilator.
- Pulmonary clearance of vasoactive intestinal peptide.
- Vasoactive peptides in the lung, with special reference to vasoactive intestinal peptide.
- Vasoactive intestinal peptide (VIP).